MetLife Investment Management LLC Acquires 972,699 Shares of ADMA Biologics Inc $ADMA

Key Points

• MetLife Investment Management LLC increased its stake in ADMA Biologics Inc by 714.1%, acquiring a total of 972,699 shares to own about 0.47% of the company, valued at $22 million.
• Several other institutional investors, including Skandinaviska Enskilda Banken AB and SVB Wealth LLC, have recently taken new positions in ADMA Biologics, contributing to 75.68% of the stock ownership being held by institutional investors.
• ADMA Biologics recently reported a quarterly EPS of $0.15, which exceeded analysts’ estimates, while its revenue grew by 13.8% year-over-year, indicating strong business performance.

MetLife Investment Management LLC raised its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 714.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,108,911 shares of the biotechnology company's stock after buying an additional 972,699 shares during the period. MetLife Investment Management LLC owned 0.47% of ADMA Biologics worth $22,001,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. New York State Teachers Retirement System increased its stake in ADMA Biologics by 96.2% in the 1st quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock valued at $4,402,000 after buying an additional 108,800 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of ADMA Biologics by 251.6% during the 1st quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock worth $131,000 after purchasing an additional 4,715 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new position in shares of ADMA Biologics during the 1st quarter worth about $201,000. Ameriprise Financial Inc. increased its stake in shares of ADMA Biologics by 14.1% during the 4th quarter. Ameriprise Financial Inc. now owns 715,672 shares of the biotechnology company's stock worth $12,274,000 after purchasing an additional 88,542 shares during the last quarter. Finally, Penserra Capital Management LLC acquired a new position in shares of ADMA Biologics during the 1st quarter worth about $2,293,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Performance

ADMA traded down $0.12 on Friday, reaching $17.26. The company had a trading volume of 2,527,726 shares, compared to its average volume of 3,388,413. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67. The stock has a market cap of $4.12 billion, a P/E ratio of 20.07 and a beta of 0.38. The company's fifty day moving average is $17.76 and its 200 day moving average is $18.91. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same quarter in the prior year, the business earned $0.13 EPS. ADMA Biologics's quarterly revenue was up 13.8% on a year-over-year basis. As a group, analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on ADMA. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial boosted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $27.67.

Insider Activity at ADMA Biologics

In related news, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the transaction, the director owned 478,194 shares in the company, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve Elms sold 194,749 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares in the company, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 455,621 shares of company stock worth $9,461,633. Insiders own 3.50% of the company's stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.